Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit The most intensive medical obesity therapy in the pipeline is retatrutide. Retatrutide is the "triple G," a glucose dependent insulinotropic polypeptide (GIP), glucagon like peptide 1 (GLP 1), and glucagon receptor agonist. It has demonstrated robust blood Retatrutide & AOD9604: A Deep Dive into the "Triple Plus" Protocol We know that Retatrutide is the new heavy hitter on the block, but when you add AOD9604 to the mix, you aren't Retatrutide vs CagriSema 2026: Next Gen Weight Loss Drugs Compared